116 Korean patients followed for two years after weight-loss surgery: the weight came back a little, the quality of life did not

National claims data can tell you how much weight a population lost. It cannot tell you whether they felt better. This prospective cohort ran four separate quality-of-life instruments at five time points across two years, which is the part that makes it worth reading next to the larger registry figures.

The weight curve has a shape#

Weight loss peaked at around eighteen months and then gave back a little. That pattern is well described and it is the honest thing to show a patient, because a single figure quoted at the one-year mark implies a plateau that does not occur. The regain here is modest — under three percentage points — and the two-year figure remains close to a quarter of starting body weight.

The comorbidities did not follow the weight#

Diabetes remission rose from 80.7 percent at one year to 85.7 percent at two, and hyperlipidaemia remission from 49.0 to 71.4 percent — both improving while weight was drifting back up. Hypertension sat still at 50.0 percent at both time points.

That divergence is the most interesting thing in the dataset. If metabolic improvement were simply a function of weight, these curves would track each other. They do not, which is consistent with the long-standing observation that metabolic surgery acts on glucose handling through mechanisms that are not only about mass. The cohort is far too small to establish that, and it is the direction the numbers point.

The two procedures again come out level#

37 gastric bypasses against 79 sleeve gastrectomies, with no significant differences in weight trajectory, nutritional outcomes or comorbidity improvement — the same null result the nationwide cohort of 856 patients reported on procedure choice. Two Korean datasets of different design reaching the same conclusion is worth more than either alone.

The obvious limit is size. 116 patients cannot detect a modest difference between procedures, and a null result in a small study is weak evidence of equivalence. What this cohort does add that the registry cannot is the quality-of-life measurement, and there the finding is unambiguous: all four instruments improved significantly and stayed improved, including across the period in which weight was returning.